Table 1.

Overall patients’ characteristics at the baseline.

	Overall	Intensive PK Study (n = 41)
	n = 76	Group 0 (n = 17)	Group 1 (n = 9)	Group 2 (n = 13)	Group 3 (n = 2)
Variable	Value (median [IQR]/%)	-	-	-	-
Age (median [IQR])	60 [50–70.5]	60 [51–73]	67 [48–75]	60 [48–71]	40 [17–40]
Ethnicity: Caucasian (%)	100%	-	-	-	-
Sex: Male (n (%))	47 [60%]	9 [53]	7 [78]	6 [60]	1 [50]
Albumin (g/L)	43 [40–45]	44 [39–46]	44 [43–46]	43 [42–45]	45 [40–45]
BMI	24.5 [22.2-28.2]	26 [22–31]	20 [22–24]	24 [23–30]	23 [21–23]
BSA	1.7 [1.4–2.2]	1.8 [1.5–2.3]	1.6 [1.2–1.8]	1.9 [1.7–2.2]	1.2 [1–1.3]
eGFR (mL/min)	94.5 [77.3–116.2]	86 [74–104]	91 [79–126]	100 [73–118]	112 [90–113]
AEs: yes	1	1 [6%]	-	-	-
Infection control: yes (n, (%))	36 [47%]	10 [60]	3 [30]	10 [80]	1 [50]
Diabetes: yes (n, (%))	19 [25%]	4 [23]	1 [13]	3 [23]	-
Previous therapy: yes (n, (%))	73 [96%]	17 [100]	8 [89]	13 [100]	2 [100]
N. therapy lines: 1 (n, (%)); 2: (n, (%)); 3: (n, (%))	52 [75%]; 20 [26]; 1 [1]	12 [67]; 5 [33]	4 [50]; 4 [50]	5 [40]; 8 [60]	1 [50]; 1 [50]
Length of therapy before DBV (days)	14 [14–35]	14 [14–56]	35 [23–75]	35 [28–105]	35 [14–35]
Reasons for DBV (n, (%)): previous failure; consolidation; intolerance	31 [41%]; 43 [56]; 2 [3]	9 [53]; 8 [47]	5 [55]; 4 [45]	4 [30]; 7 [55]; 2 [15]	1 [50]; 1 [50]